OncoFinder, a new algorithm for minimizing errors in high-throughput transcriptome analysis

InSilico Medicine, Inc. officially announces OncoFinder for effective pathway analysis and drug screening.

        Print
| Source: InSilico Medicine, Inc.

BALTIMORE, Md., Aug. 21, 2014 (GLOBE NEWSWIRE) -- via PRWEB - InSilico Medicine, a Baltimore-based company dedicated to aging interventions and addressing the challenges of a rapidly aging population, proposes a new concept, OncoFinder, for signalome-wide pathway analysis. This new method allows for accurate and robust cross-platform analysis of gene expression data obtained using high-throughput techniques.

The original research, published in the journal Frontiers in Molecular Biosciences, shows that the OncoFinder method significantly reduces errors introduced by transcriptome-wide experimental techniques. Scientists compared gene expression data for the same biological samples obtained by both next generation sequencing (NGS) and microarray methods, finding that these different techniques have almost no correlation between the gene expression values for all datasets analysed. In contrast, when the OncoFinder algorithm is applied to the data, a clear correlation between next generation sequencing and microarray gene expression datasets was seen.

"For several years the potential for the use of gene expression data in research and clinical applications has been underappreciated due to the inconsistency of the data coming from the various types of equipment. There is just too much variation and complexity when comparing the massive number of individual genes. But when this complexity is reduced and the gene expression is mapped onto signalling pathways, we can evaluate the pathway activation drift and analyse the changes and transitions much more effectively. The OncoFinder algorithm enables scientists to characterise the functional states of transcriptomes more accurately than before and we hope that this will become a method of choice in genetics, physiology, biomedicine and molecular diagnostics," said Alex Zhavoronkov, PhD, CEO of Insilico Medicine and co-author of the study.

The original research paper is available to view and download here ( http://journal.frontiersin.org/Journal/10.3389/fmolb.2014.00008/abstract ).

Contact
Michael Petr
Research Associate
michael.petr@insilicomedicine.com
1 (210) 835 5356

This article was originally distributed on PRWeb. For the original version including any supplementary images or video, visit http://www.prweb.com/releases/InSilico/Medicine/prweb12107521.htm

InSilico Medicine, Inc.
Qingsong Zhu, PhD

+1 4107109674